In this publication, we reported that many patients with AERD have ear/hearing-related symptoms that are related to eustachian tube dysfunction. We found that treatment with dupilumab, led to improvement in ear and hearing-related symptoms in patients with AERD. Read more…
We completed a 24-month long, survey-based study examining the health care utilization and symptom burden in patients with AERD. We found that at the end of 24 months, the participants who were on dupilumab at the start of the 2-year study…
This study showed for the first time that nasal fluid levels of oncostatin M (OSM) and IL-6 are higher in AERD patients compared to healthy controls and are reduced by dupilumab treatment. We suspect that one of the reasons that…
Aspirin-lowering and ibuprofen-bridging protocols are safe and effective for patients with aspirin-exacerbated respiratory disease to decrease aspirin dosing prior to elective surgical procedures, but were only utilized in half of surveyed participants, suggesting need for increased awareness. Click here to…
This study found that 32% of AERD patients on dupilumab for asthma or nasal polyposis had attempted a dosing interval other than every 2 weeks. Of those, 68% chose to continue with less frequent injections, most commonly every 3 weeks,…
This study demonstrates that celecoxib offers effective pain management for patients with AERD, and that non-selective NSAIDs (like ibuprofen and Naprosyn) are effective and safe for most AERD patients to take after aspirin desensitization. We found that there is a…
This study examined the validation of the questionnaires used for a prior study from our group that examined how loss of smell impacted the mental health and quality of life of patients with AERD. We determined that this new Consequences…
In this study, we evaluated 22 patients with AERD who were treated with dupilumab for 3 months, and 8 of those patients had also undergone aspirin desensitization prior to the start of dupilumab and continued on their high-dose daily aspirin…
This clinical trial compared one month of treatment with ifetroban (a medication that blocks the thromboxane A2 receptor) to placebo in patients with AERD, to see if the ifetroban treatment decreased the severity of aspirin-induced reactions. Unfortunately, there was a…
AERD is generally recognized as an adult-onset disease, however; the prevalence of AERD in pediatric patients is not well defined. In May 2022 we described a series of 6 pediatric patients with AERD, and their childhood AERD symptoms were almost identical…